stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. VSBC
    stockgist
    HomeTop MoversCompaniesConcepts
    VSBC logo

    VitaSpring Biomedical Co. Ltd.

    VSBC
    OTC
    Healthcare
    Biotechnology
    Irvine, CA, USvitaspringbio.com
    —

    At a Glance

    AI-generated

    VitaSpring Biomedical Co.

    —

    Market Cap

    —

    Revenue

    —

    Net Income

    Fundamentals

    How The Business Makes Money

    VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. in February 2020. VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, California.

    Industry Biotechnology
    Activity

    What Changed Recently

    No significant events in the past 90 days.

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    KNTPFKintor Pharmaceutical Lim...————
    PBIGFParadigm Biopharmaceutica...————
    SPHRYStarpharma Holdings Limit...————
    TOKIFTOKIF————
    POLBFPoolbeg Pharma PLC————
    AURXNuo Therapeutics, Inc.————
    IUGNFImugene Limited————
    SHIEFShield Therapeutics plc————
    Company Profile
    CIK0001697884
    ISINUS92851B1026
    CUSIP92851B102
    Phone949 202 9235
    Address400 Spectrum Center Drive, Irvine, CA, 92618, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice